Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. Dummer R, Hauschild A, Santinami M, Atkinson V, et al. N Engl J Med 2020 Sep 2. doi: 10.1056/NEJMoa2005493.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Dummer R, Hauschild A, Santinami M, Atkinson V, et al. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med 2020 Sep 2. doi: 10.1056/NEJMoa2005493.
PMID: 32877599